Suppr超能文献

服用口服抗凝剂患者的临床病史和胃肠道出血。

Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants.

机构信息

Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

出版信息

Int J Cardiol. 2021 Sep 15;339:134-137. doi: 10.1016/j.ijcard.2021.07.029. Epub 2021 Jul 17.

Abstract

BACKGROUND

Common risk factors for gastrointestinal bleeding (GIB) are advanced age and the use of antiplatelet or anticoagulants drugs for the prevention of cardiovascular diseases.

METHODS

In this prospective real-world observational study, oral anticoagulated patients were recruited and followed between June 2013 and December 2019. The primary end-point was to evaluate a possible relationship between bleeding events and patients' clinical history of gastrointestinal disease prior to the start of the therapy. The secondary end-points were time of GIB appearance and the percentage of idiopathic or provoked events, i.e., bleeding due to a gastrointestinal disease. In case of GIB event all the patients were studied by means of endoscopic procedures. Cox regression was used to calculate the relative hazard ratios (HRs) of GIB for each considered clinical variable.

RESULTS

734 patients on both VKAs or DOACs were studied. Overall, 46 hemorrhagic events were recorded: 6 were major bleeding (0.42/100 patient-years) while 43 were clinically relevant non major bleeding (2.8/100 patient-years). The Cox regression analysis did not show any relationships among GIB and the variables considered.

CONCLUSION

The patients' clinical history is neither a predictor for GIB bleeding nor a guide to the choice of the oral anticoagulant to be administered. Routinely applying bleeding risk screening, such as occult blood in the stool, should be added to the periodic laboratory checks for early recognition of patients at higher risk of GIB.

摘要

背景

胃肠道出血(GIB)的常见危险因素是年龄较大和使用抗血小板或抗凝药物预防心血管疾病。

方法

在这项前瞻性真实世界观察研究中,招募了口服抗凝治疗的患者,并在 2013 年 6 月至 2019 年 12 月期间进行随访。主要终点是评估出血事件与治疗开始前患者胃肠道疾病临床史之间可能存在的关系。次要终点是 GIB 出现时间和特发性或诱发性出血(即因胃肠道疾病引起的出血)的百分比。在发生 GIB 事件的情况下,所有患者均通过内镜检查进行研究。Cox 回归用于计算 GIB 与每个考虑的临床变量相关的相对危险比(HR)。

结果

研究了 734 名同时接受 VKA 或 DOAC 治疗的患者。总体而言,记录了 46 例出血事件:6 例为大出血(0.42/100 患者年),43 例为临床相关非大出血(2.8/100 患者年)。Cox 回归分析未显示 GIB 与所考虑的变量之间存在任何关系。

结论

患者的临床病史既不能预测 GIB 出血,也不能指导选择要使用的口服抗凝剂。应常规进行出血风险筛查,例如粪便潜血,以在定期实验室检查中早期识别出血风险较高的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验